| Dr John Schifferdecker, MD | |
|
554 Talcottville Rd, Vernon, CT 06066-2310 | |
| (860) 875-6700 | |
| (860) 870-6140 |
| Full Name | Dr John Schifferdecker |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 48 Years |
| Location | 554 Talcottville Rd, Vernon, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255344123 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 033016 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Visiting Nurse & Health Services Of Connecticut | Vernon, CT | Hospice |
| Manchester Memorial Hospital | Manchester, CT | Hospital |
| Rockville General Hospital | Rockville, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prohealth Physicians Pc | 1355246950 | 236 |
News Archive
Based on current scientific literature, gastrostomy tube (G-tube) placement or other long-term enteral access devices should be withheld or withdrawn in patients with advanced dementia or other near end-of-life conditions, according to a special report published today in the OnlineFirst version of Nutrition in Clinical Practice, the official journal of the American Society for Parenteral and Enteral Nutrition.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.
New structures of a botulism toxin interacting with a mimic of the nerve-cell protein it destroys suggest new ways to block this often-fatal interaction. Indeed, the mimic molecules have such high affinity for the toxin and bind to it so tightly that they themselves could possibly serve as anti-toxin drugs with further modification, the researchers said.
For decades, immunologists have been trying to train the transplant recipient's immune system to accept transplanted cells and organs without the long-term use of anti-rejection drugs. New University of Minnesota preclinical research shows that this is now possible.
Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited financial results for the second quarter ended June 30, 2010.
› Verified 1 days ago
| Entity Name | Prohealth Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720194053 PECOS PAC ID: 1355246950 Enrollment ID: O20031205000602 |
News Archive
Based on current scientific literature, gastrostomy tube (G-tube) placement or other long-term enteral access devices should be withheld or withdrawn in patients with advanced dementia or other near end-of-life conditions, according to a special report published today in the OnlineFirst version of Nutrition in Clinical Practice, the official journal of the American Society for Parenteral and Enteral Nutrition.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.
New structures of a botulism toxin interacting with a mimic of the nerve-cell protein it destroys suggest new ways to block this often-fatal interaction. Indeed, the mimic molecules have such high affinity for the toxin and bind to it so tightly that they themselves could possibly serve as anti-toxin drugs with further modification, the researchers said.
For decades, immunologists have been trying to train the transplant recipient's immune system to accept transplanted cells and organs without the long-term use of anti-rejection drugs. New University of Minnesota preclinical research shows that this is now possible.
Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited financial results for the second quarter ended June 30, 2010.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Schifferdecker, MD 4 Farm Springs Rd, Prohealth Physicians, Farmington, CT 06032-2573 Ph: (860) 284-5200 | Dr John Schifferdecker, MD 554 Talcottville Rd, Vernon, CT 06066-2310 Ph: (860) 875-6700 |
News Archive
Based on current scientific literature, gastrostomy tube (G-tube) placement or other long-term enteral access devices should be withheld or withdrawn in patients with advanced dementia or other near end-of-life conditions, according to a special report published today in the OnlineFirst version of Nutrition in Clinical Practice, the official journal of the American Society for Parenteral and Enteral Nutrition.
Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that additional claims for the patent family "Internalizing anti-CD74 antibodies and methods of use," were issued as U.S. Patent No. 7,772,373. The new patent, which will expire in March 2023, covers any humanized antibodies that compete for binding to CD74 with milatuzumab, or bind to the same epitope as milatuzumab.
New structures of a botulism toxin interacting with a mimic of the nerve-cell protein it destroys suggest new ways to block this often-fatal interaction. Indeed, the mimic molecules have such high affinity for the toxin and bind to it so tightly that they themselves could possibly serve as anti-toxin drugs with further modification, the researchers said.
For decades, immunologists have been trying to train the transplant recipient's immune system to accept transplanted cells and organs without the long-term use of anti-rejection drugs. New University of Minnesota preclinical research shows that this is now possible.
Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited financial results for the second quarter ended June 30, 2010.
› Verified 1 days ago
Andrea Sadowski, PA Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 Hartford Tpke, Suite N, Vernon, CT 06066 Phone: 860-872-8321 Fax: 860-875-6271 | |
Lisa Talati, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 428 Hartford Tpke, Vernon, CT 06066 Phone: 860-533-4611 | |
Dr. Madhuri Pratinidhi, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 351 Merline Rd, Suite 101, Vernon, CT 06066 Phone: 860-871-1613 Fax: 860-875-8991 | |
Momina Afrede, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 428 Hartford Tpke Ste 210, Vernon, CT 06066 Phone: 860-533-4611 | |
Mr. Eric Anthony Camyre, D.O Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 428 Hartford Tpke, Suite 210, Vernon, CT 06066 Phone: 860-533-4611 | |
Kristin Giannini, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 Hartford Tpke, Suite N, Vernon, CT 06066 Phone: 860-872-8321 Fax: 860-875-6271 |